- Home
- QNCX
as 03-13-2025 3:42pm EST
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 62.0M | IPO Year: | 2019 |
| Target Price: | $9.50 | AVG Volume (30 days): | 82.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.51 - $2.45 | Next Earning Date: | 03-31-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Quince Therapeutics Inc. News
QNCX Breaking Stock News: Dive into QNCX Ticker-Specific Updates for Smart Investing
Simply Wall St.
9 days ago
Spotlight On Fractyl Health And Two Other Intriguing Penny Stocks
Business Wire
a month ago
Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia
Business Wire
a month ago
Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Business Wire
a month ago
Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia
Business Wire
a month ago
Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia
Business Wire
a month ago
Quince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia
Business Wire
2 months ago
Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board
Simply Wall St.
2 months ago
Spotlight On US Penny Stocks For January 2025
Compare QNCX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "QNCX Quince Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.